Parkinson's-Fighting Biotech Snags $75M In Series A Funding
Prevail Therapeutics Inc., a New York biotechnology company focused on fighting neurodegenerative diseases like Parkinson's, on Thursday said it pocketed $75 million in its latest funding round thanks to investors including...To view the full article, register now.
Already a subscriber? Click here to view full article